Safety and activity of the immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients.

Antimicrob Agents Chemother

Hollis-Eden Pharmaceuticals, Inc., 4435 Eastgate Mall, Suite 400, San Diego, CA 92121, USA.

Published: July 2007

Twenty-five AIDS patients were treated with HE2000, a synthetic adrenal hormone. The drug was well tolerated and safe and reduced both the incidence of tuberculosis coinfection by 42.2% (P < 0.05) and the cumulative incidence of opportunistic infections (P < 0.05). These results warrant further clinical investigation of HE2000.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1913278PMC
http://dx.doi.org/10.1128/AAC.01446-06DOI Listing

Publication Analysis

Top Keywords

incidence tuberculosis
8
opportunistic infections
8
aids patients
8
safety activity
4
activity immune
4
immune modulator
4
modulator he2000
4
he2000 incidence
4
tuberculosis opportunistic
4
infections aids
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!